Annexon Inc at JPMorgan Healthcare Conference Transcript
&-
Welcome everyone, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad [Ant Grover, Laurea Hall, Malcolm Kuno]. Our next presenting company is Annexon. And presenting on behalf of the company, we have CEO, Douglas Love.
All right. Thank you, Anupam, and thank all of you today. We're delighted to be here to provide an update on Annexon and what promises to be a transformational 2024. This will be the year where we release our first registrational dataset. And just march ever closer towards our mission of helping millions of patients suffering from complement-mediated diseases.
I'll be making forward-looking statements this afternoon and we invite you to look at our materials on file. Annexon is a late-stage clinical company targeting the classical complement pathway to treat a host of different diseases in the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |